By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare announced after the close of the market on Wednesday that it has completed the tender offer for all outstanding shares of common and preferred stock of Clarient.

GE Healthcare announced its plan to buy the Aliso Viejo, Calif.-based molecular diagnostics and imaging firm in October for $580 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.